^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KDR rs2305945

    i
    Other names: KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
    Entrez ID:
    3791
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over2years
    c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. (PubMed, BMC Med)
    In bevacizumab-treated women diagnosed with EOC, high c-MET/VEGFR-2 co-localisation on tumour tissue and the VEGFR-2 rs2305945 G/G variant, which may be biologically related, were associated with worse survival outcomes.
    P3 data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KDR (Kinase insert domain receptor)
    |
    KDR rs2305945 • MET-H
    |
    Avastin (bevacizumab)